{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:46:58Z","timestamp":1794336418835,"version":"4.9.0"},"reference-count":152,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.pharmthera.2021.107964","type":"journal-article","created":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T23:25:18Z","timestamp":1628724318000},"page":"107964","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":256,"special_numbering":"C","title":["Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics"],"prefix":"10.1016","volume":"230","author":[{"given":"Yoshikatsu","family":"Kanai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2021.107964_bb0005","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/CCO.0b013e328356da72","article-title":"Glucose transporters in cancer metabolism","volume":"24","author":"Adekola","year":"2012","journal-title":"Current Opinion in Oncology"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0010","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1126\/science.1093131","article-title":"Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption","volume":"303","author":"Altmann","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0015","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1039\/b903035m","article-title":"Recent advances in the understanding of the interaction of antidepressant drugs with serotonin and norepinephrine transporters","volume":"25","author":"Andersen","year":"2009","journal-title":"Chemical Communications"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0020","doi-asserted-by":"crossref","first-page":"43838","DOI":"10.1074\/jbc.M305221200","article-title":"Identification of a novel system L amino acid transporter structurally distinct from heterodimeric amino acid transporters","volume":"278","author":"Babu","year":"2003","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0025","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.tips.2010.11.011","article-title":"Renal glucose reabsorption inhibitors to treat diabetes","volume":"32","author":"Bailey","year":"2011","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0030","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3945\/an.112.002113","article-title":"Eukaryotic initiation factor 2 phosphorylation and translational control in metabolism","volume":"3","author":"Baird","year":"2012","journal-title":"Advances in Nutrition"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0035","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/1748-717X-7-146","article-title":"Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer","volume":"7","author":"Barth","year":"2012","journal-title":"Radiation Oncology"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0040","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.bbamcr.2015.12.017","article-title":"Glutamine transporters in mammalian cells and their functions in physiology and cancer","volume":"1863","author":"Bhutia","year":"2016","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0045","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1158\/0008-5472.CAN-14-3745","article-title":"Amino Acid transporters in cancer and their relevance to \u201cglutamine addiction\u201d: novel targets for the design of a new class of anticancer drugs","volume":"75","author":"Bhutia","year":"2015","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0050","doi-asserted-by":"crossref","first-page":"12002","DOI":"10.1074\/jbc.M408638200","article-title":"Identification of LAT4, a novel amino acid transporter with system L activity","volume":"280","author":"Bodoy","year":"2005","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0055","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.mam.2012.12.006","article-title":"The small SLC43 family: facilitator system l amino acid transporters and the orphan EEG1","volume":"34","author":"Bodoy","year":"2013","journal-title":"Molecular Aspects of Medicine"},{"issue":"Pt 2","key":"10.1016\/j.pharmthera.2021.107964_bb0060","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1042\/bj3240535","article-title":"Expression of the surface antigen 4F2hc affects system-L-like neutral-amino-acid-transport activity in mammalian cells","volume":"324","author":"Br\u00f6er","year":"1997","journal-title":"The Biochemical Journal"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0065","doi-asserted-by":"crossref","first-page":"24467","DOI":"10.1074\/jbc.M400904200","article-title":"Molecular cloning of mouse amino acid transport system B0, a neutral amino acid transporter related to Hartnup disorder","volume":"279","author":"Br\u00f6er","year":"2004","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0070","doi-asserted-by":"crossref","first-page":"13194","DOI":"10.1074\/jbc.M115.700534","article-title":"Deletion of amino acid transporter ASCT2 (SLC1A5) reveals an essential role for transporters SNAT1 (SLC38A1) and SNAT2 (SLC38A2) to sustain glutaminolysis in cancer cells","volume":"291","author":"Br\u00f6er","year":"2016","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0075","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1152\/physrev.1990.70.1.43","article-title":"Role of amino acid transport and countertransport in nutrition and metabolism","volume":"70","author":"Christensen","year":"1990","journal-title":"Physiological Reviews"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0080","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/S0021-9258(18)91789-8","article-title":"A bicyclic amino acid to improve discriminations among transport systems","volume":"244","author":"Christensen","year":"1969","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0085","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s002590050597","article-title":"Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine","volume":"26","author":"Cook","year":"1999","journal-title":"European Journal of Nuclear Medicine"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0090","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.1158\/0008-5472.CAN-15-3376","article-title":"Genetic disruption of the multifunctional CD98\/LAT1 complex demonstrates the key role of essential amino acid transport in the control of mTORC1 and tumor growth","volume":"76","author":"Cormerais","year":"2016","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0095","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1074\/jbc.RA117.001342","article-title":"The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5)","volume":"293","author":"Cormerais","year":"2018","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0100","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1111\/jcmm.14176","article-title":"Inhibition of the amino-acid transporter LAT1 demonstrates anti-neoplastic activity in medulloblastoma","volume":"23","author":"Cormerais","year":"2019","journal-title":"Journal of Cellular and Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0105","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s002590050265","article-title":"Estimation of internal absorbed dose of L-[methyl-11C]methionine using whole-body positron emission tomography","volume":"25","author":"Deloar","year":"1998","journal-title":"European Journal of Nuclear Medicine"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0110","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.molcel.2012.09.017","article-title":"HIF2\u03b1 acts as an mTORC1 activator through the amino acid carrier SLC7A5","volume":"48","author":"Elorza","year":"2012","journal-title":"Molecular Cell"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0115","series-title":"Aromatic Amino Acid Derivatives and Medicinal Compositions. US Patent 7,345,068 B2","author":"Endou","year":"2008"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0120","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nature742","article-title":"Molecular identification of a renal urate anion exchanger that regulates blood urate levels","volume":"417","author":"Enomoto","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0125","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/36349","article-title":"Complementation of dominant suppression implicates CD98 in integrin activation","volume":"390","author":"Fenczik","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0130","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1073\/pnas.0404852102","article-title":"CD98hc (SLC3A2) mediates integrin signaling","volume":"102","author":"Feral","year":"2005","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0135","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.mam.2012.10.007","article-title":"The SLC3 and SLC7 families of amino acid transporters","volume":"34","author":"Fotiadis","year":"2013","journal-title":"Molecular Aspects of Medicine"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0140","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.semcancer.2005.04.005","article-title":"Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime?","volume":"15","author":"Fuchs","year":"2005","journal-title":"Seminars in Cancer Biology"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0145","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1349-7006.2011.02151.x","article-title":"Correlation of L-type amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis","volume":"103","author":"Furuya","year":"2012","journal-title":"Cancer Science"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0150","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12958-015-0054-8","article-title":"Expression and functional characterisation of System L amino acid transporters in the human term placenta","volume":"13","author":"Gaccioli","year":"2015","journal-title":"Reproductive Biology and Endocrinology"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0155","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.pharmthera.2008.09.005","article-title":"Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond","volume":"121","author":"Ganapathy","year":"2009","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0160","doi-asserted-by":"crossref","first-page":"5480","DOI":"10.1073\/pnas.1218165110","article-title":"Structure-based ligand discovery for the Large-neutral Amino Acid Transporter 1, LAT-1","volume":"110","author":"Geier","year":"2013","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0165","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/01.mnh.0000242178.44576.b0","article-title":"Molecular mechanisms and regulation of furosemide-sensitive Na-K-Cl cotransporters","volume":"15","author":"Gim\u00e9nez","year":"2006","journal-title":"Current Opinion in Nephrology and Hypertension"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0170","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ijpharm.2010.08.019","article-title":"Brain uptake of ketoprofen-lysine prodrug in rats","volume":"399","author":"Gynther","year":"2010","journal-title":"International Journal of Pharmaceutics"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0175","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1007\/s11064-016-1996-8","article-title":"Amino acid promoieties alter valproic acid pharmacokinetics and enable extended brain exposure","volume":"41","author":"Gynther","year":"2016","journal-title":"Neurochemical Research"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0180","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1006\/bbrc.1999.1051","article-title":"Malignant transformation of NIH3T3 cells by overexpression of early lymphocyte activation antigen CD98","volume":"262","author":"Hara","year":"1999","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0185","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.4049\/jimmunol.1300923","article-title":"LAT1 is a critical transporter of essential amino acids for immune reactions in activated human T cells","volume":"191","author":"Hayashi","year":"2013","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0190","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/all.14019","article-title":"LAT1-specific inhibitor is effective against T cell-mediated allergic skin inflammation","volume":"75","author":"Hayashi","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0195","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/jcp.25076","article-title":"Dexamethasone Downregulates SLC7A5 Expression and Promotes Cell Cycle Arrest, Autophagy and Apoptosis in BeWo Cells","volume":"231","author":"He","year":"2016","journal-title":"Journal of Cellular Physiology"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0200","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.mam.2012.12.009","article-title":"The ABCs of membrane transporters in health and disease (SLC series): introduction","volume":"34","author":"Hediger","year":"2013","journal-title":"Molecular Aspects of Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.107964_bb0205","doi-asserted-by":"crossref","DOI":"10.3390\/nu10010023","article-title":"Characterisation of L-type amino acid transporter 1 (LAT1) expression in human skeletal muscle by immunofluorescent microscopy","volume":"10","author":"Hodson","year":"2017","journal-title":"Nutrients"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0210","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/jso.24160","article-title":"Clinicopathological significance of LAT1 and ASCT2 in patients with surgically resected esophageal squamous cell carcinoma","volume":"113","author":"Honjo","year":"2016","journal-title":"Journal of Surgical Oncology"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0215","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1248\/bpb.31.2126","article-title":"Evaluation of amino acid-mustard transport as L-type amino acid transporter 1 (LAT1)-mediated alkylating agents","volume":"31","author":"Hosoya","year":"2008","journal-title":"Biological & Pharmaceutical Bulletin"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0220","doi-asserted-by":"crossref","first-page":"8853","DOI":"10.18632\/oncotarget.2593","article-title":"Hypoxia-inducible factors enhance glutamate signaling in cancer cells","volume":"5","author":"Hu","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0225","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1440-1827.2011.02650.x","article-title":"High expression of L-type amino-acid transporter 1 (LAT1) in gastric carcinomas: comparison with non-cancerous lesions","volume":"61","author":"Ichinoe","year":"2011","journal-title":"Pathology International"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0230","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1016\/j.celrep.2017.10.082","article-title":"Slc3a2 mediates branched-chain amino-acid-dependent maintenance of regulatory T cells","volume":"21","author":"Ikeda","year":"2017","journal-title":"Cell Reports"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0235","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/j.1365-2559.2009.03300.x","article-title":"L-type amino acid transporter 1 expression is a prognostic marker in patients with surgically resected stage I non-small cell lung cancer","volume":"54","author":"Imai","year":"2009","journal-title":"Histopathology"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0240","first-page":"4819","article-title":"Inhibition of L-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer","volume":"30","author":"Imai","year":"2010","journal-title":"Anticancer Research"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0245","first-page":"399","article-title":"18F alpha-methyl tyrosine PET studies in patients with brain tumors","volume":"40","author":"Inoue","year":"1999","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0250","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1148\/radiology.220.1.r01jl1654","article-title":"Detection of malignant tumors: whole-body PET with fluorine 18 alpha-methyl tyrosine versus FDG--preliminary study","volume":"220","author":"Inoue","year":"2001","journal-title":"Radiology"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0255","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2011.01.038","article-title":"CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth","volume":"19","author":"Ishimoto","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0260","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1111\/cas.12529","article-title":"Expression of L-type amino acid transporter 1 (LAT1) as a prognostic and therapeutic indicator in multiple myeloma","volume":"105","author":"Isoda","year":"2014","journal-title":"Cancer Science"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0265","first-page":"432","article-title":"Radiolabeled amino acids: basic aspects and clinical applications in oncology","volume":"42","author":"Jager","year":"2001","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0270","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1124\/jpet.120.000235","article-title":"Interaction of halogenated tyrosine\/phenylalanine derivatives with organic anion transporter 1 in the renal handling of tumor imaging probes","volume":"375","author":"Jin","year":"2020","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0275","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0006-8993(00)02758-X","article-title":"The 4F2hc\/LAT1 complex transports L-DOPA across the blood-brain barrier","volume":"879","author":"Kageyama","year":"2000","journal-title":"Brain Research"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0280","doi-asserted-by":"crossref","first-page":"6369","DOI":"10.1158\/1078-0432.CCR-07-1294","article-title":"Fluorine-18-alpha-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: a clinicopathologic study","volume":"13","author":"Kaira","year":"2007","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0285","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1378\/chest.06-2160","article-title":"Diagnostic usefulness of fluorine-18-alpha-methyltyrosine positron emission tomography in combination with 18F-fluorodeoxyglucose in sarcoidosis patients","volume":"131","author":"Kaira","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0290","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/sj.bjc.6604235","article-title":"Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer","volume":"98","author":"Kaira","year":"2008","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0295","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1111\/j.1349-7006.2008.00969.x","article-title":"L-type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms","volume":"99","author":"Kaira","year":"2008","journal-title":"Cancer Science"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0300","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.lungcan.2008.12.015","article-title":"Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in stage I pulmonary adenocarcinoma","volume":"66","author":"Kaira","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0305","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.2967\/jnumed.109.066837","article-title":"18F-FMT uptake seen within primary cancer on PET helps predict outcome of non-small cell lung cancer","volume":"50","author":"Kaira","year":"2009","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0310","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/bjc.2012.310","article-title":"Prognostic significance of L-type amino-acid transporter 1 expression in surgically resected pancreatic cancer","volume":"107","author":"Kaira","year":"2012","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0315","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1186\/1471-2407-13-482","article-title":"Clinical significance of L-type amino acid transporter 1 expression as a prognostic marker and potential of new targeting therapy in biliary tract cancer","volume":"13","author":"Kaira","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0320","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s12253-013-9624-2","article-title":"Clinicopathological significance of L-type amino acid transporter 1 (LAT1) expression in patients with adenoid cystic carcinoma","volume":"19","author":"Kaira","year":"2013","journal-title":"Pathology Oncology Research"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0325","first-page":"1161","article-title":"Prognostic significance of L-type amino acid transporter 1 (LAT1) expression in patients with ovarian tumors","volume":"7","author":"Kaira","year":"2015","journal-title":"American Journal of Translational Research"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0330","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1007\/s11095-008-9532-4","article-title":"Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC\/MS\/MS method combined with novel in-silico peptide selection criteria","volume":"25","author":"Kamiie","year":"2008","journal-title":"Pharmaceutical Research"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0335","doi-asserted-by":"crossref","first-page":"23629","DOI":"10.1074\/jbc.273.37.23629","article-title":"Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98)","volume":"273","author":"Kanai","year":"1998","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0340","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/cas.14761","article-title":"\u03b1-Emitting cancer therapy using 211At-AAMT targeting LAT1","volume":"112","author":"Kaneda-Nakashima","year":"2021","journal-title":"Cancer Science"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0345","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijpharm.2018.04.025","article-title":"Structural properties for selective and efficient l-type amino acid transporter 1 (LAT1) mediated cellular uptake","volume":"544","author":"K\u00e4rkk\u00e4inen","year":"2018","journal-title":"International Journal of Pharmaceutics"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0350","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1042\/BJ20080622","article-title":"Interaction of tryptophan derivatives with SLC6A14 (ATB0,+) reveals the potential of the transporter as a drug target for cancer chemotherapy","volume":"414","author":"Karunakaran","year":"2008","journal-title":"The Biochemical Journal"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0355","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1254\/jphs.12124FP","article-title":"Establishment of stable cell lines with high expression of heterodimers of human 4F2hc and human amino acid transporter LAT1 or LAT2 and delineation of their differential interaction with \u03b1-alkyl moieties","volume":"119","author":"Khunweeraphong","year":"2012","journal-title":"Journal of Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0360","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.tem.2009.05.008","article-title":"ATF4-dependent transcription mediates signaling of amino acid limitation","volume":"20","author":"Kilberg","year":"2009","journal-title":"Trends in Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0365","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0005-2736(02)00516-3","article-title":"Characterization of the system L amino acid transporter in T24 human bladder carcinoma cells","volume":"1565","author":"Kim","year":"2002","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0370","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/MNH.0b013e32832f2fcb","article-title":"Molecular physiology of the thiazide-sensitive sodium-chloride cotransporter","volume":"18","author":"Ko","year":"2009","journal-title":"Current Opinion in Nephrology and Hypertension"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0375","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1227\/01.neu.0000316018.51292.19","article-title":"Enhanced tumor growth elicited by L-type amino acid transporter 1 in human malignant glioma cells","volume":"62","author":"Kobayashi","year":"2008","journal-title":"Neurosurgery"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0380","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jphs.2017.01.006","article-title":"Structure-activity relationship of a novel series of inhibitors for cancer type transporter L-type amino acid transporter 1 (LAT1)","volume":"133","author":"Kongpracha","year":"2017","journal-title":"Journal of Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0385","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/s41594-019-0237-7","article-title":"Cryo-EM structure of the human L-type amino acid transporter 1 in complex with glycoprotein CD98hc","volume":"26","author":"Lee","year":"2019","journal-title":"Nature Structural & Molecular Biology"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0390","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s00726-011-0983-2","article-title":"Leucine nutrition in animals and humans: mTOR signaling and beyond","volume":"41","author":"Li","year":"2011","journal-title":"Amino Acids"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0395","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S1476-5586(04)80054-X","article-title":"L-type amino acid transporter-1 overexpression and melphalan sensitivity in Barrett\u2019s adenocarcinoma","volume":"6","author":"Lin","year":"2004","journal-title":"Neoplasia"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0400","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41580-019-0199-y","article-title":"mTOR at the nexus of nutrition, growth, ageing and disease","volume":"21","author":"Liu","year":"2020","journal-title":"Nature Reviews. Molecular Cell Biology"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0405","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/jcp.21366","article-title":"The x(c)- cystine\/glutamate antiporter: a potential target for therapy of cancer and other diseases","volume":"215","author":"Lo","year":"2008","journal-title":"Journal of Cellular Physiology"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0410","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1002\/ijc.30371","article-title":"LAT1 is a putative therapeutic target in endometrioid endometrial carcinoma","volume":"139","author":"Marshall","year":"2016","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0415","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1097\/00001756-200011090-00021","article-title":"Expression of a system L neutral amino acid transporter at the blood-brain barrier","volume":"11","author":"Matsuo","year":"2000","journal-title":"Neuroreport"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0420","doi-asserted-by":"crossref","first-page":"7250","DOI":"10.1038\/ncomms8250","article-title":"LAPTM4b recruits the LAT1-4F2hc Leu transporter to lysosomes and promotes mTORC1 activation","volume":"6","author":"Milkereit","year":"2015","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0425","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1254\/jphs.08232FP","article-title":"Establishment and characterization of mammalian cell lines stably expressing human L-type amino acid transporters","volume":"108","author":"Morimoto","year":"2008","journal-title":"Journal of Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0430","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1073\/pnas.1519959113","article-title":"Novel cystine transporter in renal proximal tubule identified as a missing partner of cystinuria-related plasma membrane protein rBAT\/SLC3A1","volume":"113","author":"Nagamori","year":"2016","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0435","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s00726-015-2158-z","article-title":"Structure-activity relations of leucine derivatives reveal critical moieties for cellular uptake and activation of mTORC1-mediated signaling","volume":"48","author":"Nagamori","year":"2016","journal-title":"Amino Acids"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0440","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.1038\/onc.2012.638","article-title":"Redox regulation in stem-like cancer cells by CD44 variant isoforms","volume":"32","author":"Nagano","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0445","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41588-020-00753-3","article-title":"The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer","volume":"53","author":"Najumudeen","year":"2021","journal-title":"Nature Genetics"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0450","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1111\/hepr.12431","article-title":"Expression of amino acid transporters (LAT1, ASCT2 and xCT) as clinical significance in hepatocellular carcinoma","volume":"45","author":"Namikawa","year":"2015","journal-title":"Hepatology Research"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0455","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.bcp.2017.07.006","article-title":"Potent inhibitors of human LAT1 (SLC7A5) transporter based on dithiazole and dithiazine compounds for development of anticancer drugs","volume":"143","author":"Napolitano","year":"2017","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0460","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/ijc.21866","article-title":"L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors","volume":"119","author":"Nawashiro","year":"2006","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0465","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41594-019-0240-z","article-title":"Insights into L-type heteromeric amino acid transporters","volume":"26","author":"Newstead","year":"2019","journal-title":"Nature Structural & Molecular Biology"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0470","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cell.2008.11.044","article-title":"Bidirectional transport of amino acids regulates mTOR and autophagy","volume":"136","author":"Nicklin","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0475","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1042\/bj3580693","article-title":"Molecular events involved in up-regulating human Na+-independent neutral amino acid transporter LAT1 during T-cell activation","volume":"358","author":"Nii","year":"2001","journal-title":"The Biochemical Journal"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0480","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s12253-015-9954-3","article-title":"Expression of Amino Acid Transporters (LAT1 and ASCT2) in Patients with Stage III\/IV Laryngeal Squamous Cell Carcinoma","volume":"21","author":"Nikkuni","year":"2015","journal-title":"Pathology Oncology Research"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0485","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1007\/s00259-013-2477-9","article-title":"Diagnostic usefulness of 18F-FAMT PET and L-type amino acid transporter 1 (LAT1) expression in oral squamous cell carcinoma","volume":"40","author":"Nobusawa","year":"2013","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0490","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1349-7006.2009.01386.x","article-title":"L-type amino acid transporter 1 inhibitors inhibit tumor cell growth","volume":"101","author":"Oda","year":"2010","journal-title":"Cancer Science"},{"issue":"11","key":"10.1016\/j.pharmthera.2021.107964_bb0495","doi-asserted-by":"crossref","DOI":"10.1128\/MCB.00427-16","article-title":"Essential roles of L-type amino acid transporter 1 in syncytiotrophoblast development by presenting fusogenic 4F2hc","volume":"37","author":"Ohgaki","year":"2017","journal-title":"Molecular and Cellular Biology"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0500","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.bbrc.2011.02.135","article-title":"Oncogenicity of L-type amino-acid transporter 1 (LAT1) revealed by targeted gene disruption in chicken DT40 cells: LAT1 is a promising molecular target for human cancer therapy","volume":"406","author":"Ohkawa","year":"2011","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0505","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1111\/cas.13021","article-title":"Efficacy of system l amino acid transporter 1 inhibition as a therapeutic target in esophageal squamous cell carcinoma","volume":"107","author":"Ohshima","year":"2016","journal-title":"Cancer Science"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0510","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/cas.14756","article-title":"Proteomics and phosphoproteomics reveal key regulators associated with cytostatic effect of amino acid transporter LAT1 inhibitor","volume":"112","author":"Okanishi","year":"2021","journal-title":"Cancer Science"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0515","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s10637-020-00924-3","article-title":"First-in-human phase I study of JPH203, an L-type amino acid transporter 1 inhibitor, in patients with advanced solid tumors","volume":"38","author":"Okano","year":"2020","journal-title":"Investigational New Drugs"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0520","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ijpharm.2012.12.029","article-title":"Functional characterization and molecular expression of large neutral amino acid transporter(LAT1) in human prostate cancer cells","volume":"443","author":"Patel","year":"2013","journal-title":"International Journal of Pharmaceutics"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0525","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00259-003-1118-0","article-title":"Whole-body distribution and dosimetry of O-(2-[18F]fluoroethyl)-L-tyrosine","volume":"30","author":"Pauleit","year":"2003","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0530","first-page":"374","article-title":"Comparison of O-(2-18F-fluoroethyl)-L-tyrosine PET and 3-123I-iodo-alpha-methyl-L-tyrosine SPECT in brain tumors","volume":"45","author":"Pauleit","year":"2004","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0535","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/1476-4598-12-169","article-title":"CD98hc (SLC3A2) drives integrin-dependent renal cancer cell behavior","volume":"12","author":"Poettler","year":"2013","journal-title":"Molecular Cancer"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0540","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1006\/bbrc.1999.0206","article-title":"Human LAT1, a subunit of system L amino acid transporter: molecular cloning and transport function","volume":"255","author":"Prasad","year":"1999","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0545","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s13046-020-01762-0","article-title":"Amino acid transporter LAT1 in tumor-associated vascular endothelium promotes angiogenesis by regulating cell proliferation and VEGF-A-dependent mTORC1 activation","volume":"39","author":"Quan","year":"2020","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0550","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s00259-002-0821-6","article-title":"O-(2-[(18)F]Fluoroethyl)-L-tyrosine (FET): a tracer for differentiation of tumour from inflammation in murine lymph nodes","volume":"29","author":"Rau","year":"2002","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0555","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejps.2014.09.025","article-title":"Amino acid ester prodrugs conjugated to the \u03b1-carboxylic acid group do not display affinity for the L-type amino acid transporter 1 (LAT1)","volume":"66","author":"Rautio","year":"2015","journal-title":"European Journal of Pharmaceutical Sciences"},{"issue":"Pt 3","key":"10.1016\/j.pharmthera.2021.107964_bb0560","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1042\/bj3560719","article-title":"Role of the system L permease LAT1 in amino acid and iodothyronine transport in placenta","volume":"356","author":"Ritchie","year":"2001","journal-title":"The Biochemical Journal"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0565","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/leu.2014.338","article-title":"L-type amino-acid transporter 1 (LAT1): a therapeutic target supporting growth and survival of T-cell lymphoblastic lymphoma\/T-cell acute lymphoblastic leukemia","volume":"29","author":"Rosilio","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0570","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1440-1827.2008.02319.x","article-title":"L-type amino-acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer","volume":"59","author":"Sakata","year":"2009","journal-title":"Pathology International"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0575","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.2967\/jnumed.107.046615","article-title":"Differential uptake of O-(2-18F-fluoroethyl)-L-tyrosine, L-3H-methionine, and 3H-deoxyglucose in brain abscesses","volume":"48","author":"Salber","year":"2007","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0580","first-page":"1152","article-title":"TA1, a highly conserved oncofetal complementary DNA from rat hepatoma, encodes an integral membrane protein associated with liver development, carcinogenesis, and cell activation","volume":"55","author":"Sang","year":"1995","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0585","first-page":"E7697","article-title":"Global metabolic reprogramming of colorectal cancer occurs at adenoma stage and is induced by MYC","volume":"114","author":"Satoh","year":"2017","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0590","first-page":"E4111","article-title":"Functional expression of sodium-glucose transporters in cancer","volume":"112","author":"Scafoglio","year":"2015","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0595","doi-asserted-by":"crossref","first-page":"19745","DOI":"10.1074\/jbc.274.28.19745","article-title":"Identification and functional characterization of a Na+\u2212independent neutral amino acid transporter with broad substrate selectivity","volume":"274","author":"Segawa","year":"1999","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0600","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0014-5793(99)00304-X","article-title":"Structural requirement of leucine for activation of p70 S6 kinase","volume":"447","author":"Shigemitsu","year":"1999","journal-title":"FEBS Letters"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0605","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/CMR.0000000000000181","article-title":"Prognostic significance of L-type amino acid transporter 1 (LAT1) expression in cutaneous melanoma","volume":"25","author":"Shimizu","year":"2015","journal-title":"Melanoma Research"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0610","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10120-016-0610-8","article-title":"Dose-escalation study for the targeting of CD44v+ cancer stem cells by sulfasalazine in patients with advanced gastric cancer (EPOC1205)","volume":"20","author":"Shitara","year":"2017","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0615","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1158\/0008-5472.CAN-08-2483","article-title":"Expression of human organic cation transporter 3 in kidney carcinoma cell lines increases chemosensitivity to melphalan, irinotecan, and vincristine","volume":"69","author":"Shnitsar","year":"2009","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0620","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/ni.2556","article-title":"Control of amino-acid transport by antigen receptors coordinates the metabolic reprogramming essential for T cell differentiation","volume":"14","author":"Sinclair","year":"2013","journal-title":"Nature Immunology"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0625","doi-asserted-by":"crossref","first-page":"23740","DOI":"10.1074\/jbc.274.34.23740","article-title":"Cloning and functional expression of a human Na(+) and Cl(\u2212)-dependent neutral and cationic amino acid transporter B(0+)","volume":"274","author":"Sloan","year":"1999","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0630","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1007\/s00259-005-0047-5","article-title":"Differentiation of tumour and inflammation: characterisation of [methyl-3H]methionine (MET) and O-(2-[18F]fluoroethyl)-L-tyrosine (FET) uptake in human tumour and inflammatory cells","volume":"33","author":"Stober","year":"2006","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0635","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1124\/jpet.104.082255","article-title":"Mediation of highly concentrative uptake of pregabalin by L-type amino acid transport in Chinese hamster ovary and Caco-2 cells","volume":"313","author":"Su","year":"2005","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0640","first-page":"164","article-title":"Expression of glucose transporters in cancers","volume":"1835","author":"Szablewski","year":"2013","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0645","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/01.ATV.0000134377.17680.26","article-title":"Lysophosphatidylcholine enhances cytokine production of endothelial cells via induction of L-type amino acid transporter 1 and cell surface antigen 4F2","volume":"24","author":"Takabe","year":"2004","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0650","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.cell.2016.11.013","article-title":"Impaired amino acid transport at the blood brain barrier is a cause of autism spectrum disorder","volume":"167","author":"T\u0103rlungeanu","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0655","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1038\/bjc.2014.178","article-title":"Prognostic significance of amino-acid transporter expression (LAT1, ASCT2, and xCT) in surgically resected tongue cancer","volume":"110","author":"Toyoda","year":"2014","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0660","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0026-895X(24)12322-X","article-title":"Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition","volume":"61","author":"Uchino","year":"2002","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0665","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1007\/s00424-003-1086-z","article-title":"CATs and HATs: the SLC7 family of amino acid transporters","volume":"447","author":"Verrey","year":"2004","journal-title":"Pfl\u00fcgers Archiv"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0670","doi-asserted-by":"crossref","first-page":"7525","DOI":"10.1158\/0008-5472.CAN-11-1821","article-title":"Androgen receptor and nutrient signaling pathways coordinate the demand for increased amino acid transport during prostate cancer progression","volume":"71","author":"Wang","year":"2011","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0675","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1093\/jnci\/djt241","article-title":"Targeting amino acid transport in metastatic castration-resistant prostate cancer: effects on cell cycle, cell growth, and tumor development","volume":"105","author":"Wang","year":"2013","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0680","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.18632\/oncotarget.27552","article-title":"Targeted alpha therapy using astatine (211At)-labeled phenylalanine: A preclinical study in glioma bearing mice","volume":"11","author":"Watabe","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0685","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/IGC.0000000000000123","article-title":"L-type amino acid transporter 1 expression increases in well-differentiated but decreases in poorly differentiated endometrial endometrioid adenocarcinoma and shows an inverse correlation with p53 expression","volume":"24","author":"Watanabe","year":"2014","journal-title":"International Journal of Gynecological Cancer"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0690","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jphs.2016.01.001","article-title":"Transport of 3-fluoro-L-\u03b1-methyl-tyrosine (FAMT) by organic ion transporters explains renal background in [(18)F]FAMT positron emission tomography","volume":"130","author":"Wei","year":"2016","journal-title":"Journal of Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0695","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/cas.12878","article-title":"Specific transport of 3-fluoro-l-\u03b1-methyl-tyrosine by LAT1 explains its specificity to malignant tumors in imaging","volume":"107","author":"Wei","year":"2016","journal-title":"Cancer Science"},{"issue":"12","key":"10.1016\/j.pharmthera.2021.107964_bb0700","article-title":"Developing selective L-amino acid transport 1 (LAT1) inhibitors: a structure-activity relationship overview","volume":"7","author":"Wempe","year":"2019","journal-title":"Archives of Medical Research"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0705","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.2967\/jnumed.112.103069","article-title":"Transport of 3-fluoro-L-\u03b1-methyl-tyrosine by tumor-upregulated L-type amino acid transporter 1: a cause of the tumor uptake in PET","volume":"53","author":"Wiriyasermkul","year":"2012","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0710","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/cas.12602","article-title":"Boronophenylalanine, a boron delivery agent for boron neutron capture therapy, is transported by ATB0,+, LAT1 and LAT2","volume":"106","author":"Wongthai","year":"2015","journal-title":"Cancer Science"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0715","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1152\/physrev.00055.2009","article-title":"Biology of human sodium glucose transporters","volume":"91","author":"Wright","year":"2011","journal-title":"Physiological Reviews"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0720","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1074\/mcp.M400207-MCP200","article-title":"Metabolic activation-related CD147-CD98 complex","volume":"4","author":"Xu","year":"2005","journal-title":"Molecular & Cellular Proteomics"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0725","doi-asserted-by":"crossref","first-page":"28178","DOI":"10.1074\/jbc.273.43.28178","article-title":"Branched-chain amino acids are essential in the regulation of PHAS-I and p70 S6 kinase by pancreatic beta-cells. A possible role in protein translation and mitogenic signaling","volume":"273","author":"Xu","year":"1998","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0730","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/j.juro.2015.11.071","article-title":"Up-regulation of LAT1 during antiandrogen therapy contributes to progression in prostate cancer cells","volume":"195","author":"Xu","year":"2016","journal-title":"The Journal of Urology"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0735","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.canlet.2008.10.035","article-title":"System L amino acid transporter inhibitor enhances anti-tumor activity of cisplatin in a head and neck squamous cell carcinoma cell line","volume":"276","author":"Yamauchi","year":"2009","journal-title":"Cancer Letters"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0740","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41586-019-1011-z","article-title":"Structure of the human LAT1-4F2hc heteromeric amino acid transporter complex","volume":"568","author":"Yan","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0745","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41421-021-00247-4","article-title":"Mechanism of substrate transport and inhibition of the human LAT1-4F2hc amino acid transporter","volume":"7","author":"Yan","year":"2021","journal-title":"Cell Discovery"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0750","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0005-2736(01)00384-4","article-title":"Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines","volume":"1514","author":"Yanagida","year":"2001","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0755","doi-asserted-by":"crossref","first-page":"12681","DOI":"10.1111\/jcmm.15840","article-title":"Small molecule inhibitors provide insights into the relevance of LAT1 and LAT2 in materno-foetal amino acid transport","volume":"24","author":"Zaugg","year":"2020","journal-title":"Journal of Cellular and Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2021.107964_bb0760","doi-asserted-by":"crossref","first-page":"5000","DOI":"10.1016\/j.bmcl.2016.09.001","article-title":"LAT1 activity of carboxylic acid bioisosteres: evaluation of hydroxamic acids as substrates","volume":"26","author":"Zur","year":"2016","journal-title":"Bioorganic & Medicinal Chemistry Letters"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725821001662?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725821001662?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:18:47Z","timestamp":1759011527000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725821001662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":152,"alternative-id":["S0163725821001662"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107964","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107964","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107964"}}